Evidence map›Paper›PMID 38063385›Full record

ArticleMicrobiology spectrum2024

Nitroxoline resistance is associated with significant fitness loss and diminishes

Felix Deschner, Timo Risch, Claas Baier, Dirk Schlüter, Jennifer Herrmann, Rolf Müller

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Felix DeschnerMicrobial Natural Products, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) and Department of Pharmacy Saarland University , Saarbrücken, Germany.
Timo RischMicrobial Natural Products, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) and Department of Pharmacy Saarland University , Saarbrücken, Germany.
Claas BaierInstitute for Medical Microbiology and Hospital Epidemiology, Hannover Medical School (MHH) , Hannover, Germany.
Dirk SchlüterGerman Centre for Infection Research (DZIF) , Braunschweig, Germany.
Jennifer HerrmannMicrobial Natural Products, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) and Department of Pharmacy Saarland University , Saarbrücken, Germany.
Rolf MüllerMicrobial Natural Products, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) and Department of Pharmacy Saarland University , Saarbrücken, Germany.ORCID 0000-0002-1042-5665
German Center for Infection Research · DEMedizinische Hochschule Hannover · DE

Funding

MIP Pharma GmbH n/a
6 · The paper itself

Abstract

importanceAntimicrobial resistance (AMR) poses a global threat and requires the exploration of underestimated treatment options. Nitroxoline, an effective broad-spectrum antibiotic, does not suffer from high resistance rates in the clinics but surprisingly, it is not heavily used yet. Our findings provide compelling evidence that Nitroxoline resistance renders bacteria unable to cause an infection

Indexed as

Escherichia coli InfectionsNitroquinolinesUrinary Tract InfectionsAnti-Bacterial AgentsAnti-Infective Agents, UrinaryEscherichia coliHumansVirulenceAnti-Bacterial AgentsAnti-Infective Agents, UrinaryNitroquinolinesnitroxolineantibiotic resistancefitnessgenome analysismetabolismnitroxolineproteomicsurinary tract infectionvirulence

Identifiers

PMID38063385
PMCPMC10782962
OpenAlexW4389488838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.